Comprehensive management of patients with type 2 diabetes: Establishing priorities of care

American Journal of Managed Care

Volumn 7, Issue 10 SUPPL., 2001, Pages

  Kendall, D M ^a   Bergenstal, R M ^a  

^a INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN II ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; CERIVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; UNINDEXED DRUG;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DIABETES CONTROL; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MARKER; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; STANDARD; TREATMENT OUTCOME; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; COMPREHENSIVE HEALTH CARE; DIABETES MELLITUS, TYPE 2; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; RISK FACTORS; SELF CARE; UNITED STATES;

EID: 0034859260     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Global burden of diabetes mellitus, 1995-2025: Prevalence, numerical estimates, and projections
2. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994
3. The progressive cost of complications in type 2 diabetes mellitus
4. Health care expenditures for people with diabetes mellitus, 1992
5. The cost to health plans of poor glycemic control
6. Economic consequences of diabetes mellitus in 1997
7. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
8. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
9. Heart disease and diabetes
10. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study
11. Diabetes mellitus and cardiovascular disease in women
12. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry
13. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects
14. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
15. Hypertension in the US adult population: Where are we now?
16. Management of dyslipidemia in adults with diabetes
17. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: Diagnostic criteria and performance revisited
18. Coordinated performance measurement for the management of adult diabetes
19. Position statement: Standards of medical care for patients with diabetes mellitus
20. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
21. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
22. Prevention of type 2 diabetes mellitus in high-risk patients
23. Insulin resistance and diabetic complications
24. Report of the expert committee on the diagnosis and classification of diabetes mellitus
25. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
26. Effectiveness of self-management training in type 2 diabetes
27. Studies of educational interventions and outcomes in diabetic adults: A meta-analysis revisited
28. Cost effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus
29. Diabetes education outcomes: What educators are doing
30. Meta-analysis of the effects of educational and psychosocial interventions on the management of diabetes mellitus
31. Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. Results from the Medical Outcomes Study
32. How adults learn and change
33. The health belief model: Explaining health behavior through expectancies
34. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
35. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland
36. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle diabetic men: A general population study
37. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes
38. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
39. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: Subgroup analysis of the Scandinavin Simvastatin Survival Study
40. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
41. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
42. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
43. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
44. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study
45. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study
46. Nonhypoglycemic effects of thiazolidinediones
47. The effect of glitazones on lipid profiles
48. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated?
49. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
50. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
51. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
52. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group
53. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
54. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
55. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension (ABCD)
56. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
57. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
58. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
59. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
60. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
61. Sixth report
62. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). ALLHAT Research Group
63. Troglitazone inhibits vascular smooth-muscle cell growth and intimal hyperplasia
64. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
65. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
66. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
67. Pioglitazone attenuates diet-induced hypertension in rats
68. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
69. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes
70. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
71. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus
72. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial
73. Overview of 6 years' therapy of type II diabetes: A progressive disease
74. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
75. Pharmacologic therapy for type 2 diabetes mellitus
76. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
77. Triple oral antidiabetic therapy in type 2 diabetes mellitus
78. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group
79. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
80. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group
81. Treatment of diabetic retinopathy
82. Early photocoagulation for diabetic retinopathy: ETDRS report number 9
83. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus
84. Diabetic nephropathy
85. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
86. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
87. Albuminuria and poor glycemic control predict mortality in NIDDM
88. Aspirin therapy in diabetes
89. Aspirin use among adults with diabetes: Estimates from the third National Health and Nutrition Examination Survey
90. Preventive foot care in people with diabetes
91. The use of influenza and pneumococcal vaccines in people with diabetes
92. Smoking and diabetes
93. Intervention study for smoking cessation in diabetic patients: A randomized controlled trial in both clinical and primary care settings
94. Effects of intensive diabetes therapy on neuropsychological functioning in adults in the Diabetes Control and Complications Trial
95. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
96. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial